Epigenetics

Epigenetics is the control of gene expression without altering the DNA sequence, including DNA methylation, genomic imprinting, maternal effects, gene silencing, nucleolus dominant, dormant transposon activation, and RNA editing. In contrast to classical genetics, which focuses on the effects of gene sequences on biological functions, epigenetics focuses on the mechanisms by which these "epigenetic phenomena" are established and maintained.

Cat. No.	Product name
BP13857	Ginkgolide C
BP13857	Ginkgolide C, a natural product, can enhance the cardiac function of rats in the body.
BP13856	GeA-69
BP13856	GeA-69 (GeA69) is a selective and allosteric PARP14 macrodomain 2 (MD2) inhibitor (Kd: 0.86 μM in ITC assays).
BP13855	GDC-0339
BP13855	GDC-0339 is discovered as a potential treatment of multiple myeloma. GDC-0339 is an orally bioavailable and well-tolerated inhibitor of the pan-Pim kinase (Kis: 0.03 nM, 0.1 nM, and 0.02 nM for Pim1, Pim2, and Pim3, respectively).
BP13854	Gardenin A
BP13854	Gardenin A has antihyperlipidemic and hepatoprotective effects, it also promotes neuritogenesis through the activation of MAPK/ERK-, PKC-, and PKA-dependent, but not TrkA-dependent, CREB signaling pathways in PC12 cells.
BP13853	Ganodermanondiol
BP13853	Ganodermanondiol exhibits potent cytoprotective effects on t-BHP-induced hepatotoxicity in human liver-derived HepG2 cells, presumably through Nrf2-mediated antioxidant enzymes and AMPK.
BP13852	γ-Oryzanol
BP13852	Gamma-Oryzanol is a natural nutrient extract isolated from rice bran oil that contains a mixture of sterols and ferulic acids, which may aid in the destruction of free radicals in the skin. It has recently been researched for its ability to slow the progress of melanin pigmentation by intercepting the ultraviolet rays at the skin's surface and hindering their transmission.
BP13851	Gambogenic acid
BP13851	Gambogenic acid is a natural product,is an effective inhibitor of EZH2,with anticancer activity.
BP13850	G007-LK
BP13850	G007-LK is a selective inhibitor of TNKS1 and TNKS2, with IC50s of 46 nM and 25 nM, respectively.
BP13849	Fucosterol
BP13849	Fucosterol is isolated from E. stolonifera with anti-diabetic, anti-adipogenic and anti-cancer activities. It regulates adipogenesis via modulation of PPARα and C/EBPα expression.
BP13848	FT895
BP13848	FT895 is a selective and potent selective HDAC11 inhibitor with an IC50 of 3 nM.
BP13847	Fluzoparib
BP13847	fluzoparib is a novel, potent, and orally available inhibitor of PARP, potentially for the treatment of solid tumours.
BP13846	Flufenamic acid
BP13846	Flufenamic acid is an anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically.
BP13845	FL-411
BP13845	FL-411 is a potent and selective BRD4 inhibitor with an IC50 of 0.43±0.09 μM for BRD4.
BP13844	FKBP12 PROTAC dTAG-7
BP13844	FKBP12 PROTAC dTAG-7 (dTAG-7) also is a selective degrader of BET bromodomain transcriptional co-activator BRD4 by bridging BET bromodomains to an E3 ubiquitin ligase CRBN. FKBP12 PROTAC dTAG-7 (dTAG-7) is a heterobifunctional degrader. FKBP12 PROTAC dTAG-7 (dTAG-7) is a degrader of FKBP12F36V with expression of FKBP12F36V in-frame with a protein of interest.
BP13843	FKBP12 PROTAC dTAG-13
BP13843	FKBP12 PROTAC dTAG-13 (dTAG-13) is a degrader of FKBP12F36V with expression of FKBP12F36V in-frame with a protein of interest. FKBP12 PROTAC dTAG-13 (dTAG-13) also is a selective degrader of BET bromodomain transcriptional co-activator BRD4 by bridging BET bromodomains to an E3 ubiquitin ligase CRBN. FKBP12 PROTAC dTAG-13 (dTAG-13) is a PROTAC-based heterobifunctional degrader.
BP13842	FHD-286
BP13842	FHD-286 is an inhibitor of BRM/BRG1 ATPase and can be used for studies on the treatment of BAF-related disorders such as acute myeloid leukemia.
BP13841	FG-2216
BP13841	FG-2216 is a potent HIF-prolyl hydroxylase inhibitor for the PDH2 enzyme (IC50: 3.9 uM); orally bioavailable and induced reversible and significant Epo induction in vivo.
BP13840	EZM 2302
BP13840	EZM2302 is a selective, and orally available arginine methyltransferase CARM1 inhibitor (IC50: 6 nM).
BP13839	EZM0414
BP13839	EZM0414 is a selective SEDT2 inhibitor that is mostly used to study diffuse large B lymphocytoma and recurrent or refractory multiple myeloma.
BP13838	Exifone
BP13838	Exifone is a mixed, nonessential activator of HDAC1 that is capable of binding to both free and substrate-bound enzyme, resulting in an increased relative maximal rate of HDAC1-catalyzed deacetylation.